Concert Pharma (CNCE) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharmaceuticals (CNCE) PT Lowered to $26 at Mizuho Securities
November 1, 2018 11:17 AM EDTMizuho Securities analyst Didei Yang lowered the price target on Concert Pharmaceuticals (NASDAQ: CNCE) to $26.00 (from $27.00) while maintaining a Buy rating following earnings.
Yang highlights that, importantly, the company is on track to report CTP-543 phase 2 data (4mg and 8mg... More
